Dra. Kreina Sharela Vega Cano

POSICIÓ ACTUAL
Unitat de Càncer Gastrointestinal, Hospital Universitari Vall d’Hebron & VHIO – Barcelona, Espanya
Maig 2024 – Actualitat
FORMACIÓ I CERTIFICACIONS
● Màster en Oncologia Mèdica – SEOM (Sociedad Española de Oncología Médica), 2023–2024
● Màster en Oncologia Molecular – Universidad Rey Juan Carlos / CNIO, 2022–2023
● Certificació ESMO – Superació de l’examen de la European Society for Medical Oncology, 2023
● Residència en Oncologia Mèdica – Hospital Universitari Vall d’Hebron, 2019–2024
● Llicenciatura en Medicina (MD) – Universidad Mayor de San Simón, Bolívia, 2011–2016

PERTINENÇA A SOCIETATS CIENTÍFIQUES
● European Society for Medical Oncology (ESMO)
● Sociedad Española de Oncología Médica (SEOM)
● Societat Catalano-Balear d’Oncologia
● Grup Espanyol de Tractament de Tumors Digestius

PUBLICACIONS (SELECCIÓ)
● Álvarez-Gallego R, Macarulla T, Laquente B, Peinado P, Castet F, Muñoz C, Fabregat-Franco C, Vega-Cano KS, et al. A Phase II Trial to Assess the Evolution of the KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant NALIRIFOX. American Journal of Clinical Oncology. 2025.
● Vega Cano KS, Florian Castet, Virginia Genovesi, Eduardo Teran, Teresa Macarulla. Lenvatinib en el carcinoma hepatocelular avanzado: posicionamiento actual y perspectivas futuras. Revisiones en Cáncer. Acceptat, en premsa (2025).
● Muñoz-Martín AJ, Castet F, Soto J, Vega Cano KS, et al. MDM2 amplification in a real-world cohort of patients with biliary tract cancer from the Spanish RETUD gastrointestinal registry. ESMO Gastrointest Oncol. 2025;8(C):100187.
● Cruellas M, Papakonstantinou A, López-Fernández A, Vega KS, et al. Identifying germline pathogenic variants in breast cancer using tumor sequencing. The Breast. 2025;81:102511.
● Vega Cano KS, Marmolejo Castañeda DH, Escrivá-de-Romaní S, Saura C. Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends. Cancers (Basel). 2023;15(1):51.
● Mirallas Viñas O, Martin Cullell B, Navarro V, Alonso M, Vega Cano KS, et al. Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool). Lancet Reg Health Eur. 2024;46:101063.
● Galip Can Uyar, Mirallas O, Baskurt K, Martin-Cullell B, Yesilbas E, Recuero-Borau J, Kaya S, Navarro-Garcé V, Eryildiz Yucel S, Vega Cano KS, et al. Prediction of 90-day mortality among cancer patients with unplanned hospitalisation: a retrospective validation study of three prognostic scores. Lancet Reg Health Eur. 2025;54.
● Vega-Cano KS, Cordero-Vázquez E, Mestre-Torres J. Hypoglycemia as a form of presentation of pituitary infiltration by lymphoma. Med Clin (Barc). 2021;156(7):362–363.
● Saoudi González N, Salvà F, Ros J, Baraibar I, Rodríguez-Castells M, Vega-Cano KS, et al. Unravelling the Complexity of Colorectal Cancer: Heterogeneity, Clonal Evolution, and Clinical Implications. Cancers (Basel). 2023;15(16):4020.

COMUNICACIONS A CONGRESSOS (COM A PRIMERA AUTORA)
● ESMO Congress 2025, Berlín, Alemanya. Clinical and molecular predictors of response to Chemotherapy (CT) in advanced Pancreatic Cancer (PC).
● SEOM 2025, Madrid, Espanya. Clinical and molecular characteristics in patients with advanced pancreatic cancer: retrospective analysis at a tertiary care center.
● EASL Congress 2025, Amsterdam, Països Baixos. Liver injury induced by CDK4/6 inhibitors for metastatic breast cancer: characterization and management.
● EASL Congress 2024, Milà, Itàlia. Combination of liver steatosis and premenopausal status is a risk factor for DILI due to CDK4/6 inhibitors as first-line treatment for metastatic breast cancer.
● ESMO Congress 2024, Barcelona, Espanya. The usefulness of pre-radiotherapy MRI in assessing pseudo-progression in patients with glioblastoma included in first-line clinical trials.
● 49è Congrés AEEH 2024, Madrid, Espanya. Hepatic steatosis in premenopausal women as a risk factor for CDK4/6 inhibitor-induced hepatotoxicity in MBC.
● ESMO Congress 2023, Madrid, Espanya. Predictive factors for Drug-Induced Liver Injury in patients with ER-positive HER2-negative metastatic Breast Cancer treated with first-line CDK4/6 inhibitors.
● XVII Jornada Científica de Recerca Vall d’Hebron 2023, Barcelona, Espanya. Predictive factors for DILI in patients with ER-positive HER2-negative metastatic Breast Cancer treated with first-line CDK4/6 inhibitors.
● SEOM 2023, Barcelona, Espanya. Característiques clinicopatològiques i moleculars de dos tumors poc freqüents: carcinoma d’apèndix cecal i adenocarcinoma d’intestí prim.
● World Congress on Gastrointestinal Cancer (ESMO WGI) 2023, Barcelona, Espanya. Comparison of clinicopathological and molecular features of two rare entities: appendiceal carcinoma and small bowel adenocarcinoma.
● ESMO Breast Cancer 2023, Berlín, Alemanya. Liver toxicity in patients with ER-positive HER2-negative metastatic breast cancer treated with first-line CDK4/6 inhibitors.
● SEOM 2021, Barcelona, Espanya. HOSPITAL SCORE as a prognostic factor for readmission and Overall Survival (OS) in cancer patients admitted to a tertiary center.